Figure 2. Combined antibody therapy with agonistic anti-4-1BB and anti-CTLA-4 antibodies does not delay growth of B16.F10-GP tumors in GP tolerant Alb-1 mice.

Mice (n = 10-11 mice/group) were inoculated s.c. in the right flank with 10⁶ B16.F10-GP melanoma cells at day 0. Grey lines indicate mice that did not receive any treatment. Black lines indicate mice treated i.p. with 200 µg anti-4-1BB at day 9 and 12 plus 100 µg anti-CTLA-4 at day 5 and 50 µg anti-CTLA-4 at day 7 and 9 pt. A) Mortality of tumor bearing mice as a function of time. P-values: a vs. b = 0.8740 B) Tumor volumes as a function of time; data are presented as mean ± SEM. P-values: a vs. b = 0.9992.